Recombinant Coagulation Factors Market to Reach $9,939.7 Million by 2020
The growth of this market is primarily attributed to the increasing number of hemophilia patients, growing diagnosis rates, and rising number of research and development on coagulation factors. In addition, increasing prophylactic treatment for hemophilia across the globe is further expected to drive the growth of this market.
Wembley, United Kingdom, January 17, 2016 --(PR.com)-- Meticulous Research announced the release of a new market research report titled, “Global Recombinant Coagulation Factors Market Outlook: 2015-2020.” The report analyzes the major drivers, restraints, opportunities, and challenges that have a long and short-term impact on its growth across the globe. This latest publication from Meticulous Research states that the global global recombinant coagulation factors market would reach $9,939.7 million in 2020 and grow at a CAGR of 7.6% during the forecast period of 2015 to 2020.
The global recombinant coagulation factors market has witnessed major growth over the past few years. The growth of this market is primarily attributed to the increasing number of hemophilia patients, growing diagnosis rates, and rising number of research and development on coagulation factors. In addition, increasing prophylactic treatment for hemophilia across the globe is further expected to drive the growth of this market. However, the high cost of hemophilia treatment and low cost plasma coagulation factor alternatives to recombinant coagulation factors are hampering the growth of this market. Many players are focusing towards Asia Pacific market as this market is most lucrative for the recombinant coagulation factors.
The global recombinant coagulation factors market is expected to reach $9,939.7 million in 2020 and grow at a CAGR of 7.6% during the forecast period of 2015 to 2020. The global market is segmented on the basis of products, hemophilia type, and geography. On the basis of product, recombinant coagulation factors are segmented into three classes, namely, recombinant factor VIII, recombinant factor IX, and VonWillebrandfactor. By hemophilia type, global recombinant coagulation factor is divided into hemophilia A and hemophilia B. The market is further analyzed by end-users into hospitals and clinics, research organizations, and academic institutes. Geographically, the market is divided into North America, Europe, Asia, and rest of the world which is further analyzed at a country level.
Browse Full In-Depth Report at (Copy and paste the link)-http://www.meticulousresearch.com/research/1141/
In 2014, the recombinant factor VIII accounted for the largest share of the global recombinant coagulation factor market. The large share of this segment can be attributed to increasing number of hemophilia A patients and rising prophylaxis treatment. In the same year, North America dominated the market, with the largest share of 37.8% followed by Europe and Asia-Pacific. The increasing number of hemophilia patients in the U.S., growing diagnosis rate, and rising prophylactic treatment for prevention of bleeding helped the growth of this market. In addition, rising research on recombinant factor VIII is further expected to drive the growth of this market.
Major companies in the global recombinant coagulation factors market are Baxter International Inc. (U.S.), Grifols International SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Novo Nordisk A/S (Denmark), Biogen Idec (U.S.), Bayer AG (Germany),Kedrion S.P.A. (Italy), and Pfizer Inc. (U.S.).
About Meticulous Research
We are Meticulous. We are one of the leading market research and consulting company focusing on medical devices, biotechnology, healthcare IT, pharmaceuticals, food and beverages, and agriculture domains. We provide solutions to our clients through our market research support, data management services & advanced analytical skills. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation and analysis of data including qualitative and quantitative research with the finest team of analysts.
We focus on client satisfaction by delivering excellent market research solutions which help organizations to adapt, sustain, and grow in the changing business environment.
Contact:
sales@meticulousresearch.com
Visit: http://www.meticulousresearch.com/
The global recombinant coagulation factors market has witnessed major growth over the past few years. The growth of this market is primarily attributed to the increasing number of hemophilia patients, growing diagnosis rates, and rising number of research and development on coagulation factors. In addition, increasing prophylactic treatment for hemophilia across the globe is further expected to drive the growth of this market. However, the high cost of hemophilia treatment and low cost plasma coagulation factor alternatives to recombinant coagulation factors are hampering the growth of this market. Many players are focusing towards Asia Pacific market as this market is most lucrative for the recombinant coagulation factors.
The global recombinant coagulation factors market is expected to reach $9,939.7 million in 2020 and grow at a CAGR of 7.6% during the forecast period of 2015 to 2020. The global market is segmented on the basis of products, hemophilia type, and geography. On the basis of product, recombinant coagulation factors are segmented into three classes, namely, recombinant factor VIII, recombinant factor IX, and VonWillebrandfactor. By hemophilia type, global recombinant coagulation factor is divided into hemophilia A and hemophilia B. The market is further analyzed by end-users into hospitals and clinics, research organizations, and academic institutes. Geographically, the market is divided into North America, Europe, Asia, and rest of the world which is further analyzed at a country level.
Browse Full In-Depth Report at (Copy and paste the link)-http://www.meticulousresearch.com/research/1141/
In 2014, the recombinant factor VIII accounted for the largest share of the global recombinant coagulation factor market. The large share of this segment can be attributed to increasing number of hemophilia A patients and rising prophylaxis treatment. In the same year, North America dominated the market, with the largest share of 37.8% followed by Europe and Asia-Pacific. The increasing number of hemophilia patients in the U.S., growing diagnosis rate, and rising prophylactic treatment for prevention of bleeding helped the growth of this market. In addition, rising research on recombinant factor VIII is further expected to drive the growth of this market.
Major companies in the global recombinant coagulation factors market are Baxter International Inc. (U.S.), Grifols International SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Novo Nordisk A/S (Denmark), Biogen Idec (U.S.), Bayer AG (Germany),Kedrion S.P.A. (Italy), and Pfizer Inc. (U.S.).
About Meticulous Research
We are Meticulous. We are one of the leading market research and consulting company focusing on medical devices, biotechnology, healthcare IT, pharmaceuticals, food and beverages, and agriculture domains. We provide solutions to our clients through our market research support, data management services & advanced analytical skills. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation and analysis of data including qualitative and quantitative research with the finest team of analysts.
We focus on client satisfaction by delivering excellent market research solutions which help organizations to adapt, sustain, and grow in the changing business environment.
Contact:
sales@meticulousresearch.com
Visit: http://www.meticulousresearch.com/
Contact
Meticulous Research
John Pitt
918055561003
www.meticulousresearch.com/
John Pitt
918055561003
www.meticulousresearch.com/
Contact
Categories